#concept #macro #dealmaking

# M&A Tracker

Tracking major mergers and acquisitions relevant to portfolio.

---

## Pending deals (2026)

| Acquirer | Target | Value | Status | Sector |
|----------|--------|-------|--------|--------|
| [[Merck]] | [[Revolution Medicines]] | $32B | In talks | Pharma |

---

## Closed deals (2024-2025)

| Date | Acquirer | Target | Value | Sector |
|------|----------|--------|-------|--------|
| Dec 2025 | [[NVIDIA]] | [[Groq]] | $20B | AI chips |
| Oct 2025 | [[Broadcom]] | VMware | $69B | Software |
| Aug 2024 | [[Home Depot]] | SRS Distribution | $18B | Retail |
| Dec 2023 | [[Pfizer]] | Seagen | $43B | Pharma |
| Oct 2023 | [[Exxon]] | Pioneer | $60B | Energy |
| Oct 2023 | [[Microsoft]] | Activision | $69B | Gaming |

---

## Blocked/failed deals

| Date | Acquirer | Target | Value | Reason |
|------|----------|--------|-------|--------|
| 2018 | [[Qualcomm]] | NXP | $44B | China approval |
| 2022 | [[NVIDIA]] | Arm | $40B | Regulatory |
| 2020 | [[Visa]] | Plaid | $5B | DOJ antitrust |

---

## 2026 outlook

**JPMorgan M&A head (Jan 2026):** Record year expected. $5.1T in deals in 2025 (2nd best ever). CEOs seeking scale amid geopolitical risk.

**Hot sectors:**
- Pharma (patent cliffs driving consolidation)
- AI infrastructure
- Energy transition
- Financial services

**Deal drivers:**
- Private equity dry powder ($1T+)
- Corporate balance sheets strong
- Rate cuts improving financing
- Geopolitical risk → scale for resilience

---

## Pharma M&A wave

Patent cliffs driving "multi tens of billions" appetite:

| Company | Cliff drug | Expiry | M&A appetite |
|---------|------------|--------|--------------|
| [[Merck]] | [[Keytruda]] | 2028 | High ($32B Revolution) |
| [[Pfizer]] | Eliquis/Ibrance | 2026-27 | High (post-Seagen) |
| [[AbbVie]] | Humira | 2023 (hit) | Rebuilding |
| [[Bristol-Myers]] | Opdivo | 2028 | Active |

---

## AI/Tech M&A

| Acquirer | Target | Value | Rationale |
|----------|--------|-------|-----------|
| [[NVIDIA]] | [[Groq]] | $20B | Inference chips, SRAM hedge |
| [[NVIDIA]] | SchedMD | — | Slurm scheduler (ecosystem) |
| [[NVIDIA]] | Run:AI | — | Kubernetes orchestration |
| [[NVIDIA]] | Mellanox | $7B (2020) | Networking |

**Pattern:** NVIDIA buying infrastructure competitors depend on.

---

## Regulatory environment

| Region | Stance | Key cases |
|--------|--------|-----------|
| US (FTC) | Aggressive under Khan, softening? | MSFT-ATVI approved |
| EU | Active | Google, Apple cases |
| China | Strategic blocker | Qualcomm-NXP |
| UK (CMA) | Aggressive | MSFT-ATVI delayed |

---

*Updated 2026-01-17*

---

## Related

- [[AI consolidation]] — Big Tech acqui-hire pattern
- [[Private equity]] — PE deal activity
- [[Pharma]] — patent cliff M&A wave
